Eli Lilly gets an accelerated review from the FDA

Article Excerpt

Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products—and it now has an obesity drug with a bright future that’s being fast-tracked by the FDA. ELI LILLY & CO., $329.29, is a buy. The company (New York symbol LLY; TSINetwork Rating: Above Average) (www.lilly.com; Shares o/s: 950.2 million; Market cap: $318.3 billion; Dividend yield: 1.2%) said that the U.S. Food and Drug Administration (FDA) has now agreed to a quick review of its diabetes drug Mounjaro to treat obesity, months after a study showed it helped people lose more than 20% of their weight. The FDA granted the “fast track” status to the drug, which makes it eligible for an expedited review. The company now plans to submit data on a rolling basis this year and expects more data early next year. The developments come as obesity remains a major U.S. health concern, with the disease estimated to affect more than 40% of the population and cost nearly $173 billion annually. The FDA had already approved Mounjaro…